Sudler & Hennessey named global AOR for developmental arthritis med

Share this article:
Sudler & Hennessey (S&H) has been selected by AstraZeneca as the global agency partner of record for the developmental arthritis treatment PN400.

S&H duties will include developing the strategy, pre-launch branding and launch campaign for the drug.

PN400 is an investigational fixed dose combination of naproxen and immediate release esomeprazole under co-development with specialty drugmaker Pozen. PN 400 is currently in phase III development for patients who require chronic non-steroidal anti-inflammation drug (NSAID) treatment for arthritis pain and are at risk for NSAID associated gastric ulcers.

An NDA is targeted for the first half of 2009, according to AstraZeneca and Pozen.
Share this article:

Email Newsletters

More in News

Eli Lilly and BI's Jardiance hits shelves

Eli Lilly and BI's Jardiance hits shelves

The new SGLT-2 inhibitor is on shelves less than a month after FDA approval.

PhRMA Urges Court to Reject Off-Label Promotion Case

PhRMA Urges Court to Reject Off-Label Promotion Case

The Pharmaceutical Research and Manufacturers of America (PhRMA) says a California federal court should dismiss a whistleblower's False Claims Act suit against three drug companies on First Amendment grounds

Five things for Pharma Marketers to know: Tuesday, August 26

Five things for Pharma Marketers to know: Tuesday, ...

Merck and Pfizer pursue new pembrolizumab research, black box warnings are linked to fewer court visits, and the WHO says it needs $430M to fight Ebola.